<DOC>
	<DOCNO>NCT02081469</DOCNO>
	<brief_summary>To evaluate effectiveness safety tenofovir different treatment duration prevent HBV relapse patient malignancy receive chemotherapy off-treatment chemotherapy .</brief_summary>
	<brief_title>Prophylaxis CHB Patients With Malignant Tumor Receiving Chemotherapy</brief_title>
	<detailed_description>This study aim evaluate effectiveness safety tenofovir prevent HBV relapse HBV carrier malignant tumor follow chemotherapy . Approximately 100 patient plan receive chemotherapy malignant tumor invite participate trail . A 1 less 1-week tenofovir prophylaxis treatment administer subject prior chemotherapy eligible subject randomly assign extend 24-week prophylaxis group A 48-week prophylaxis group B 1:1 ratio end chemotherapy . The subject could stop withdrawn study earlier HBV relapse need receive another course chemotherapy respectively . The relapse episode follow 24 week end prophylaxis therapy . Data collection take place screening , every cyclic visit chemotherapy , end chemotherapy , follow prophylaxis period , every 4 week follow-up period . Patients group treat tenofovir antiviral agent accord investigator judgement HBV relapse discontinuation tenofovir therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>1 . Male female 18 70 year age 2 . Patients histologically prove malignant tumor plan receive chemotherapy enrollment 3 . Hepatitis B virus ( HBV ) carrier fulfill one follow criterion : seropositive HBsAg , HBsAg negative , AntiHBc positive HBV DNA detectable define HBV DNA &gt; 20 IU/mL ( Roche Taqman real time assay ) . 4 . Patients ALT â‰¤ 2 x ULN ( upper limit normal ) 5 . Normal Cr mg/dL eGFR &gt; 80 mL/min 6 . Life expectancy &gt; 1 year 7 . Willing able provide write informed consent 1 . Females pregnant/nursing intention pregnant within study period 2 . Documented hepatitis C virus ( HCV ) coinfection 3 . Patients current major systemic disease active infection , significant cardiac disease , poor control diabetes mellitus , osteopenia osteoporosis investigator consider significant risk 4 . Current use hepatitis B prophylaxis medication 5 . Decompensated liver cirrhosis 6 . Current previous use chemotherapy 7 . Use investigational product medicine within 1 month prior initiation study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Reactivation</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>